FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs

FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28